DCM
DAFNA Capital Management Portfolio holdings
AUM
$362M
1-Year Est. Return
0.48%
1 Year Est. Return
-0.48%
AUM
$353M
AUM Growth
-$40.7M
(-10%)
Holding
90
Top Buys
| 1 | +$2.91M | |
| 2 | +$2.58M | |
| 3 | +$1.81M | |
| 4 |
Inogen
INGN
|
+$1.78M |
| 5 |
Denali Therapeutics
DNLI
|
+$1.74M |
Top Sells
| 1 | +$3.58M | |
| 2 | +$3.07M | |
| 3 | +$1.59M | |
| 4 |
Alkermes
ALKS
|
+$875K |
| 5 |
BioCryst Pharmaceuticals
BCRX
|
+$816K |
Sector Composition
| 1 | Healthcare | 85.64% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Sutro Biopharma
STRO
$67.8M
| $284K | 0.08% |
437,079
|
|
||
77
Aprea Therapeutics
APRE
$7.22M
| $280K | 0.08% |
137,174
|
|
||
78
BiomX
PHGE
$10.5M
| $223K | 0.06% |
401,136
|
|
||
|
NVRO
79
DELISTED
NEVRO CORP.
NVRO
| $222K | 0.06% |
38,000
|
|
||
80
Black Diamond Therapeutics
BDTX
$223M
| $217K | 0.06% |
140,000
|
|
||
81
Spero Therapeutics
SPRO
$134M
| $90K | 0.03% |
125,000
|
|
||
82
Tenaya Therapeutics
TNYA
$213M
| $27K | 0.01% |
+47,319
|
|
||
83
Masimo
MASI
$7.67B
| – | – |
-3,000
|
|
||
84
Acrivon Therapeutics
ACRV
$57.2M
| – | – |
-112,414
|
|
||
85
Perspective Therapeutics
CATX
$162M
| – | – |
-130,169
|
|
||
86
Compass Therapeutics
CMPX
$711M
| – | – |
-158,394
|
|
||
|
CNTA
87
Centessa Pharmaceuticals
CNTA
$2.95B
| – | – |
-47,453
|
|
||
|
SLRN
88
DELISTED
ACELYRIN
SLRN
| – | – |
-87,989
|
|
||
89
Vir Biotechnology
VIR
$679M
| – | – |
-100,000
|
|